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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S462Results: At week 35, guinea pigs in the control group spontaneously
developed signiﬁcant cartilage lesions with mild synovial inﬂamma-
tion. The histological scores of cartilage lesions and synovitis were
well correlated with the increased level of serum biomarkers. Histo-
logically, all treatments signiﬁcantly reduced the cartilage degradation
score (p < 0.01), but only oleuropein signiﬁcantly decreased synovitis
(p < 0.05) compared to the control group. Furthermore, oleuropein
decreased serum PGE2 levels at week 35 (p < 0.01). Serum COLL2-1
and Fib3-1 were decreased by rutin and the combination of rutin and
curcumin, Fib3-2 was only decreased by the combination of rutin and
curcumin, while COLL2-1NO2 was signiﬁcantly decreased by all
treatments (p < 0.05).
Conclusions: Oleuropein and rutin with or without curcumin sig-
niﬁcantly slowed down the progression of spontaneous osteoarthritis
lesions in guinea pigs. While no additive effect was seen in the curcu-
min and rutin group, the differential effects of oleuropein or rutin on
inﬂammatory and cartilage catabolic markers suggest an interesting
combination for future studies in osteoarthritis protection.
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THE SELECTIVE CATHEPSIN K INHIBITOR MIV-711 PREVENTS
SUBCHONDRAL AND CANCELLOUS BONE LOSS IN RABBITS
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E. Lindstrom y, U. Grabowska y, M. Larson z, N. Shah x, V. Yoder Otto x,
C. Jerome x. yMedivir AB, Huddinge, Sweden; z Ibex, Logan, UT, USA;
xNumira, Salt Lake City, UT, USA
Purpose: Subchondral bone is often affected in osteoarthritis patients.
These abnormalities can be manifested as subchondral bone loss, bone
sclerosis, bone marrow lesions and osteophyte formation depending on
disease stage. We evaluated the effect of anterior cruciate ligament
transection (ACLT) on subchondral and cancellous bone in rabbits and
whether the selective cathepsin K inhibitor MIV-711 could reverse the
ACLT-evoked changes.
Methods: New Zealand white rabbits aged 9-10 months old were
subjected to ACLT (n ¼ 21) or sham surgery (n ¼ 6) of the right
femorotibial joint. One week after surgery, ACLT rabbits were treated
with either vehicle (n ¼ 7), 30 mmol/kg (n ¼ 7), or 100 mmol/kg MIV-
711 (n ¼ 7), while the sham group received vehicle. Treatments were
given orally once daily for 7 weeks until sacriﬁce. Plasma samples
were collected on Days 1, 10, 22 and 45 for determination of MIV-711
concentrations. After sacriﬁce, subchondral bone parameters were
quantiﬁed using mCT.
Results: Treatment with MIV-711 resulted in a dose-dependent
increase in circulating concentrations of MIV-711. Similar pharmaco-
kinetic proﬁles were seen on each day assessed. ACLTcaused thinning of
the subchondral bone plate that was dose-dependently reversed by
MIV-711. Figure 1 shows subchondral bone plate thickness repre-
sentative of the group mean values for average plate thickness. ACLT
evoked a 14% loss in femur subchondral bone plate thickness compared
to the vehicle-treated sham group (sham: 346 6 mmvs. ACLT: 296 16
mm, p < 0.05).
The bone loss induced by ACLT was reversed by MIV-711 (30 mmol/kg:
347  10 mm; 100 mmol/kg: 353  8 mm, p < 0.05 vs. ACLT vehicle forFigure 1. Representative subchondral bone thickness maps.Ăboth groups). Similar ﬁndings were found when assessing femur
subchondral bone plate volume (sham: 50.8  2.5 mm3 vs. ACLT:
45.5 3.1 mm3) with full reversal by MIV-711 (30 mmol/kg: 53.7  0.8
mm3; 100 mmol/kg: 55.6  2.0 mm3, p < 0.05 vs. ACLT vehicle for both
groups). ACLT also caused a 15% decrease in tibial subchondral bone
plate thickness (sham: 383  19 mm vs. ACLT: 324  14 mm, p < 0.05)
which was reversed by MIV-711 (30 mmol/kg: 383  15 mm; 100 mmol/
kg: 401  8 mm, p < 0.05 vs. ACLT vehicle for both groups). Tibial
subchondral bone volume was decreased by 17% in response to ACLT
(sham: 40.3  1.1 mm3 vs. ACLT: 33.4  1.7 mm3) with full reversal by
MIV-711 (30 mmol/kg: 39.0  2.0 mm3; 100mmol/kg: 41.2  0.9 mm3, p
< 0.05 vs. ACLT vehicle for both groups). In general, the bone loss was
most pronounced in lateral sites. Similar trends were seen when
evaluating the bone volume fraction (BV/TV) of cancellous bone
although with larger variation. Again, the highest degree of ACLT-
evoked bone loss was seen in lateral sites. MIV-711 attenuated can-
cellous bone loss in the lateral femur (BV/TV; sham: 0.383  0.020;
ACLT: 0.312  0.018; 30 mmol/kg: 0.342  0.029; 100 mmol/kg: 0.357 
0.013) and fully prevented cancellous bone loss in the lateral tibia (BV/
TV; sham: 0.497  0.028; ACLT: 0.376  0.031; 30 mmol/kg: 0.460 
0.034; 100 mmol/kg: 0.481  0.020, p < 0.05 vs. ACLT vehicle for 100
mmol/kg group).
Conclusions: The results demonstrate that ACLT, a preclinical rabbit
model of osteoarthritis, causes signiﬁcant bone loss in the subchondral
bone plate and in subchondral cancellous bone in both femur and tibia.
The bone loss is reversed by the selective cathepsin K inhibitor MIV-711
at clinically relevant concentrations.
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Purpose: Interleukin-1 (IL-1) is a potent catabolic cytokine thought to
play a major role in the development and progression of osteoarthritis
(OA) both in terms of disease (structural progression) and symptoms
(pain and functional deterioration). In a mouse model of OA, simulta-
neous inhibition of IL-1a and IL-1b with mouse anti-IL-1a/b dual vari-
able domain-immunoglobulin (DVD-Ig) reduced OA progression to a
greater extent than inhibition of either isoform alone, supporting
investigation of this mechanism of action in human trials for OA disease
modiﬁcation. The current objective is to review 2 completed phase 1
clinical trials and the protocol of a phase 2 trial investigating the use of a
novel human DVD-Ig targeting IL-1a and IL-1b (ABT-981).
Methods: The ﬁrst study in humans was a phase 1, randomized, double-
blind (DB), dose escalating, placebo-controlled study designed to assess
safety, tolerability, pharmacokinetics (PK), and anti-drug antibody
(ADA) formation following a range of dose levels of ABT-981/placebo
administered via a single intravenous (IV) infusion or subcutaneous (SC)
injection in 56 healthy subjects. The second trial was a randomized, DB,
multiple ascending dose (MAD), placebo-controlled study to assess the
safety, tolerability, PK and pharmacodynamics (PD) of multiple SC
injections of ABT-981 in knee OA patients. Patients (N ¼ 36) received
either 4 doses of placebo/ABT-981 every 2 weeks (E2W) or 3 doses
every 4 weeks. PD effects were measured by a list of biomarkers in the
areas of inﬂammation, joint destruction, and remodeling (eg, serum
hsCRP, MMP9, VEGF, C1M, C2M, C3M, CRPM, VICM, and neutrophils).
Results: ABT-981 was well tolerated in healthy subjects and knee OA
patients.NoapparentADAeffect onABT-981PKand safetywasobserved in
either phase 1 trial. The adverse event proﬁle did not signiﬁcantly differ
